| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | 0 | 0 | 0 | 0 | 197.066 | 583.937 | 823.635 |
| Total Income - EUR | - | - | - | 0 | 0 | 0 | 0 | 197.066 | 583.937 | 823.635 |
| Total Expenses - EUR | - | - | - | 0 | 0 | 0 | 22.893 | 141.942 | 578.878 | 722.973 |
| Gross Profit/Loss - EUR | - | - | - | 0 | 0 | 0 | -22.893 | 55.124 | 5.059 | 100.662 |
| Net Profit/Loss - EUR | - | - | - | 0 | 0 | 0 | -22.893 | 53.168 | -788 | 85.422 |
| Employees | - | - | - | 0 | 0 | 0 | 0 | 3 | 5 | 9 |
Check the financial reports for the company - Fomixmedica S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | 0 | 0 | 0 | 49.511 | 44.506 | 16.151 | 17.424 |
| Current Assets | - | - | - | 43 | 42 | 41 | 17.397 | 55.633 | 73.817 | 125.517 |
| Inventories | - | - | - | 0 | 0 | 0 | 17.191 | 17.245 | 17.192 | 21.241 |
| Receivables | - | - | - | 0 | 0 | 0 | 0 | 26.449 | 7.145 | 54.291 |
| Cash | - | - | - | 43 | 42 | 41 | 206 | 11.939 | 49.479 | 49.985 |
| Shareholders Funds | - | - | - | 43 | 42 | 41 | -22.772 | 30.325 | 29.238 | 85.568 |
| Social Capital | - | - | - | 43 | 42 | 41 | 121 | 122 | 121 | 121 |
| Debts | - | - | - | 0 | 0 | 0 | 89.680 | 69.813 | 60.730 | 57.373 |
| Income in Advance | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8621 - 8621" | |||||||||
| CAEN Financial Year |
8621
|
|||||||||
Comments - Fomixmedica S.r.l.